LC
NBIX icon

Lindbrook Capital’s Neurocrine Biosciences NBIX Stock Holding History

Lindbrook Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$53.4K Buy
483
+110
+29% +$13.9K ﹤0.01% 974
2024
Q4 		$50.9K Buy
373
+130
+53% +$16.1K ﹤0.01% 805
2024
Q3 		$28K Buy
243
+17
+8% +$2.33K ﹤0.01% 1105
2024
Q2 		$31.1K Buy
226
+8
+4% +$1.1K ﹤0.01% 1001
2024
Q1 		$30.1K Buy
218
+9
+4% +$1.23K ﹤0.01% 1009
2023
Q4 		$27.5K Buy
209
+96
+85% +$11.1K ﹤0.01% 1013
2023
Q3 		$12.7K Buy
113
+59
+109% +$6.21K ﹤0.01% 1288
2023
Q2 		$5.09K Sell
54
-5
-8% -$489 ﹤0.01% 1795
2023
Q1 		$5.97K Sell
59
-58
-50% -$6.04K ﹤0.01% 1775
2022
Q4 		$14K Buy
117
+28
+31% +$3.28K ﹤0.01% 1260
2022
Q3 		$9K Buy
89
+39
+78% +$3.96K ﹤0.01% 1380
2022
Q2 		$5K Buy
50
+4
+9% +$369 ﹤0.01% 1550
2022
Q1 		$4K Sell
46
-42
-48% -$3.56K ﹤0.01% 1720
2021
Q4 		$7K Sell
88
-21
-19% -$1.93K ﹤0.01% 1402
2021
Q3 		$10K Hold
109
– – ﹤0.01% 995
2021
Q2 		$11K Sell
109
-9
-8% -$863 ﹤0.01% 1017
2021
Q1 		$11K Hold
118
– – ﹤0.01% 986
2020
Q4 		$11K Buy
118
+11
+10% +$1.06K ﹤0.01% 864
2020
Q3 		$10K Buy
107
+10
+10% +$1.16K ﹤0.01% 836
2020
Q2 		$12K Sell
97
-19
-16% -$2.1K ﹤0.01% 781
2020
Q1 		$10K Buy
116
+1
+0.9% +$98 ﹤0.01% 760
2019
Q4 		$12K Hold
115
– – ﹤0.01% 878
2019
Q3 		$10K Buy
115
+18
+19% +$1.68K ﹤0.01% 904
2019
Q2 		$8K Hold
97
– – ﹤0.01% 954
2019
Q1 		$8K Hold
97
– – ﹤0.01% 957
2018
Q4 		$6K Buy
+97
New +$9.29K ﹤0.01% 974

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's NBIX Position: Q1 2025 in Review

Lindbrook Capital increased its Neurocrine Biosciences (NBIX) stake by 29% in Q1 2025, buying an estimated $13.9K and bringing the position to 483 shares worth $53.4K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Lindbrook Capital first reported a position in NBIX in Q4 2018 and has held it in 26 quarters since. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Lindbrook Capital held 483 shares of Neurocrine Biosciences worth $53.4K as of Q1 2025.
  • Lindbrook Capital bought 110 Neurocrine Biosciences shares in Q1 2025, an estimated $13.9K.
  • Neurocrine Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #974 holding.
  • Lindbrook Capital first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 26 quarters since.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.